Mogrify Secures $10M Funding to Advance In Vivo Reprogramming Therapies
Mogrify, a biopharmaceutical company based in Cambridge, UK, is making significant strides in the field of in vivo reprogramming therapies. The company recently secured an additional $10M in Series A funding, bringing their total amount raised in this round to $46M. Leading the round were Astellas Venture Management and Parkwalk Advisors, with participation from Ahren Innovation Capital, Trend Investment Group, and Dr. Jonathan Milner, co-founder of Abcam Plc. With this new funding, Mogrify plans to advance their pipeline of in vivo reprogramming therapies, focusing on pre-clinical translation, platform optimization, and biopharma collaborations.
Under the leadership of CEO Dr.
Darrin M. Disley, Mogrify is leveraging its proprietary platform technologies to identify the key transcriptomic and epigenetic cell switches that control human cell fate. Their goal is to address degenerative diseases of the eye, ear, and pancreas through direct in vivo restoration of clinically valuable cell types. By doing so, they aim to transform the lives of patients suffering from vision loss, hearing loss, and diabetes. The funding secured in this round will be utilized to further advance Mogrify's pipeline of in vivo reprogramming therapies, achieving the necessary milestones for a Series B fundraise in 2024/25 and progressing their lead program into first-in-human studies.
Mogrify's innovative approach to in vivo reprogramming therapies holds great promise for the healthcare industry. By harnessing the potential of human cell fate control, the company is paving the way for advancements in treating degenerative diseases. With the support of their investors, including prominent names in the biopharmaceutical industry, Mogrify is well-positioned to drive forward the development of their pipeline and ultimately improve the lives of patients worldwide.
They've invested in Mogrify
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Astellas Venture Management | 2 investment(s) investment(s) | 4 contacts contacts | |||
2 |  Parkwalk Advisors | 9 investment(s) investment(s) | 10 contacts contacts | |||
3 |  Ahren Innovation Capital | 1 investment(s) investment(s) | 17 contacts contacts | |||
4 |  Trend Investment Group | 1 investment(s) investment(s) | more info |
Click here for a full list of 6,481+ startup investors in the UK